Narrow Results

Streamlining the Laboratories of Today for Success.

Bayer and NUS Enterprise Launch “Grants4Apps Singapore” to Drive Health Tech Innovations across Asia Pacific.

New Approaches for Cervical Cancer Treatment Being Studied in Singapore.

Arterial Tunnel Vision: Computer Tomography Provides a Clearer View of Blood Vessel Interiors.

Regular Use of Ibuprofen May Lower Lung Cancer Risk Among High-Risk Subgroups of Cigarette Smokers.

Free Trade & Investment Agreement Threatens Public Health.

New accessible sonochemical methods were developed for the functionalization of synthesized graphene oxide (GO) with copper/iron compounds and drug intercalation into their structure in aqueous solution at ambient conditions by using ultrasound (20kHz) treatment. The sonochemical formation mechanism of a new nanomaterial was revealed through the structural analysis of three types of nanocomposites: (i) copper@graphene oxide, (ii) copper/iron@graphene oxide and (iii) iron@graphene oxide. Unique copper/iron-modified graphene oxide nanocomposites can be used as nanocarriers for the anti-inflammatory drug (ketorolac) delivery in aqueous solution due to the reduced submicron size and enlarged surface area. Disintegration of the ultrasonically intercalated ketorolac followed the exponential decay curve fit at higher pH values of the aqueous solution with a higher decay constant observed in copper/iron-modified graphene oxide nanocomposites.

We present a 9-year-old girl with persistent pain and swelling of the left wrist. X-ray, magnetic resonance imaging (MRI) and bone biopsy led to the diagnosis of chronic recurrent multifocal osteomyelitis (CRMO), affecting phalangeal and metacarpal bases and distal carpal bones on the ulnar side of the wrist. She was treated with non-steroidal anti-inflammatory drugs and complete remission with no long-term sequelae was achieved. CRMO is a rare auto-inflammatory condition with infrequent involvement of the hand. The current literature is discussed. The aim of this report is to raise awareness of the condition to reduce the time to diagnosis and unnecessary antibiotic treatment and to prevent permanent disability due to the progression of the disease.

Level of Evidence: Level V (Therapeutic)